The Israel National Biotech Innovation Center (INBI) Ltd., designed to unlock Israel's world-class biomedical research for the development of new therapies, announced the official launch of its activities. Anat Cohen-Dayag, PhD, Executive Chairperson of Compugen, has been appointed Chief Executive Officer of INBI Core Ltd., a wholly owned subsidiary of INBI. Samuel Moed, Former Head of Corporate Strategy at Bristol Myers Squibb, will serve as Chairperson of INBI and INBI Core.
Founded in partnership with an unprecedented consortium of Israel's top academic and healthcare institutions, INBI brings together, for the first time, Israel's leading sources of life science innovation. Its founding partners include the following universities, research institutions and healthcare organizations (in alphabetical order): Bar-Ilan University, Beilinson Hospital - Rabin Medical Center, Ben-Gurion University of the Negev, Clalit Health Services, Hadassah Medical Center, The Hebrew University of Jerusalem, Maccabi Healthcare Services, Rambam Health Care Campus, Shaare Zedek Medical Center, Sheba Medical Center, The Technion – Israel Institute of Technology, Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv University, The University of Haifa and the Weizmann Institute of Science.
INBI is a non-profit, national center of excellence with the mission of advancing Israel's disruptive academic research into breakthrough therapeutics. This bold, new model enables INBI to harness the breadth of Israel's world class research and benefit from a centralized translational engine designed to bridge the gap between academic discovery and clinical application. INBI was catalyzed under the umbrella of 8400 The Health Network, which continues to play a central role in advancing healthcare innovation as a key growth engine for the State of Israel.